Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib with mFOLFOX in Gastrointestinal Tumors
NCT02319018Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in gastrointestinal tumor, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose and Recommended Phase II Dose at 28 days. Started Aug 2015; status: completed.
02
Drugs
alisertib
03
Conditions
gastrointestinal tumor
Beyond the preview
Go deeper on NCT02319018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319018.